We developed ARO-RAGE, an inhaled siRNA targeting RAGE, a key driver of pulmonary inflammation. In preclinical models and a first-in-human study, it achieved deep and durable RAGE silencing, and was safe and well tolerated, supporting a novel platform for inhaled RNA therapeutics.